Broad Spectrum Efficacy of Seenthil Churnam in the Management of Urinary Tract Infections

Abstract

Urinary tract infections (UTIs) are prevalent worldwide, with an estimated 11% of the global population contracting at least one infection annually. The emergence of multidrug-resistant (MDR) pathogens due to the overuse and misuse of antibiotics necessitates alternative therapeutic options. Seenthil Churnam, a traditional Siddha medicine derived from Tinospora cordifolia, has been historically used for its antimicrobial properties. This study aimed to evaluate the broad-spectrum antimicrobial activity of Seenthil Churnam against major UTI pathogens, including MDR strains. Seenthil Churnam was procured from IMPCOPS Pharmaceuticals, Chennai. Antimicrobial activity was assessed using the disc diffusion method against 40 clinical strains, including Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecalis, Staphylococcus aureus, and Candida albicans. Zones of inhibition were measured and compared to standard antibiotics (amoxicillin, ciprofloxacin) and antifungal (fluconazole) discs. Seenthil Churnam exhibited significant antimicrobial activity against all tested strains. Zones of inhibition for bacterial strains ranged from 15.5 to 19.0 mm, while the zone for Candida albicans was 20.5 mm. The efficacy of Seenthil Churnam was comparable to that of standard antibiotics, particularly against MDR strains. Seenthil Churnam demonstrated broad-spectrum antimicrobial activity, supporting its traditional use in Siddha medicine for treating UTIs. Its effectiveness against MDR pathogens positions it as a potential alternative or adjunctive therapy for managing UTIs, warranting further clinical investigation.